Endoscopic Treatment of Bronchial Carcinoid Tumors

checkorphan
Learn more about:
Carcinoid tumor
Related Access Program
British Columbia Cancer Agency – Carcinoid Tumor Johannes Czernin – Carcinoid tumor Andrei Iagaru – Carcinoid tumor
Related Clinical Trial
Bronchoscopic Laser Ablation of Peripheral Lung Tumors Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers Personalized PRRT of Neuroendocrine Tumors Clinical and Pathologic Studies in Neuroendocrine Tumors Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Active Surveillance in Early Lung Cancer Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Cabozantinib and Nivolumab for Carcinoid Tumors Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Endoscopic Treatment of Bronchial Carcinoid Tumors Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors A Study of Axitinib in Advanced Carcinoid Tumors A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Brief Title

Endoscopic Treatment of Bronchial Carcinoid Tumors

Official Title

Feasibility and Therapeutic Method of Endoscopic Treatment of Bronchial Carcinoid Tumors: 22 Years Experience of Saint-Etienne

Brief Summary

      Carcinoid tumors of the lung are considered to be a low-grade malignancy. Surgical resection
      is considered the standard approach. Recent data has shown that a complete endoscopic
      treatment could be considered. An endoscopic treatment is can be a alternative to invasive
      surgery.

Detailed Description

      The objective of this study is to evaluate the feasibility and therapeutic method of
      endoscopic treatment of bronchial carcinoid tumors.

Study Type

Observational

Primary Outcome

Complete endoscopic treatment

Secondary Outcome

 Type of endoscopic method used

Condition

Carcinoid Tumor

Intervention

Medical data collection

Study Arms / Comparison Groups

 endoscopic treatment
Description:  Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Other

Estimated Enrollment

70

Start Date

November 1995

Completion Date

December 2017

Primary Completion Date

December 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Patients treated by endoscopic approach for a carcinoid tumor at the University
             Hospital Centre of Saint-Etienne between November 1995 to December 2017.

        Exclusion Criteria:

          -  Patients treated for a recurrence of carcinoid tumor.

          -  Patients with metastatic disease.

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jean-Michel VERGNON, PhD, ,

Location Countries

France

Location Countries

France

Administrative Informations

NCT ID

NCT03723499

Organization ID

IRBN812018/CHUSTE

Responsible Party

Sponsor

Study Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Study Sponsor

Jean-Michel VERGNON, PhD, Principal Investigator, CHU SAINT-ETIENNE

Verification Date

October 2018